The Financial Industry Regulatory Authority plans to expand its High Risk Broker initiative next year, which has so far barred 16 brokers in 2013, and is planning further enhancements to BrokerCheck, FINRA CEO Richard Ketchum told Sen. Edward Markey, D-Mass., in a recent letter.
Under its High Risk Broker initiative, launched in February, Ketchum told Markey that 42 brokers have been designated as high risk by FINRA’s Office of Fraud Detection and Market Intelligence, “resulting in fast-tracked regulatory actions.” Ketchum told Markey in a Nov. 13 letter that FINRA plans to “create a dedicated enforcement team” in 2014 to go after high-risk brokers.
Markey posted Ketchum’s letter on his web site Friday.
Ketchum was responding to concerns raised by Markey in a letter, which stated that “the fact that dozens of brokers have been designated high-risk and 16 brokers have been barred from the securities industry in mere months underscores the urgent need for FINRA and the SEC to engage in much more vigorous enforcement of rogue brokers.”
Best Healthcare Equipment Stocks To Buy For 2015: Lee Enterprises Incorporated (LEE)
Lee Enterprises, Incorporated provides local news, information, and advertising services primarily in midsize or small markets in the United States. The company publishes 50 daily and 39 Sunday newspapers, 300 weekly newspapers and classified, and niche publications in 22 states; and provides retail, classified, digital, and national advertising services. It also provides digital infrastructure and digital publishing services for approximately 1,500 daily and weekly newspapers and shoppers. The company was founded in 1890 and is based in Davenport, Iowa.
Advisors' Opinion:- [By Jeff Reeves]
Newspapers are hardly a growth industry, but after such a horrible fall from grace, publisher Lee Enterprises (LEE) may be a decent investment once more.
- [By George Putnam]
Lee Enterprises (LEE) is a publisher of regional newspapers. Like many in its sector, the company struggled with competition from the Internet, and it went through a short bankruptcy at the end of 2011.
Top 5 Gas Utility Stocks For 2014: Smart Ventures Inc (SMVR)
Smart Ventures, Inc., incorporated on November 22, 2006, is an exploration-stage company. The Company focuses on exploring, acquiring, developing and producing mineral reserves. The Company had purchased certain mineral claims located in the Laurentides Region near Mont Laurier, Quebec. In June 2011, the Company acquired Metal Assets S.A. In February 2014, Smart Ventures Inc announced the closing of its acquisition of The Sanday Corporation oil and gas drilling Services Company.
As of December 31, 2009, the Company had not generated any revenues. The Company focuses on establishing and exploiting deposits of both base and precious metals.
Advisors' Opinion:- [By Peter Graham]
Small cap marijuana stocks Smart Ventures Inc (OTCMKTS: SMVR) and Vitamin Blue Inc (OTCMKTS: VTMB) jumped 40.28% and 38.6%, respectively, while hemp stock Astika Holdings Inc (OTCBB: ASKH) fell 13.75% on Friday. Moreover, only one of these small cap stocks seems to have been the subject of a few paid promotions or investor relations types of activities. So will all three of these marijuana or hemp stocks keep producing highs or lows for investors and traders alike? Here is a quick reality check:
Smart Ventures Inc (OTCMKTS: SMVR) Plans to Enter the Marijuana Edibles BusinessSmall cap Smart Ventures Inc is an independent energy company engaged in engineering extended reach drilling services, acquisition, development, production, and exploration of oil, gas and minerals internationally. On Friday, Smart Ventures Inc rose 40.28% to $0.07 for a market cap of $2.31 million plus SMVR is up 600% over the past year and down 93.3% in intermittent trading since December 2009 according to Google Finance.
Top 5 Gas Utility Stocks For 2014: Neogenomics Inc (NEO)
NeoGenomics, Inc. (NeoGenomics) operates a network of cancer-focused testing laboratories. The Company offers testing services, including Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing, this is the process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to antigens, and molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level.
The cancer testing services, that the Company offers to community-based pathologists are designed to be a natural extension of, and complementary to, the services that they perform within their own practices. In areas where the Company does not provide services to community-based pathology practices, it may directly serve oncology, dermatology, urology and other clinician practices that prefer to have a direct relationship with a laboratory for cancer-related genetic and molecular testing services. NeoGenomics services these types of clients with a global service offering where it performs both the technical and professional components of the tests ordered.
The Company offers tech-only flow cytometry and immunohistochemistry testing services. These types of testing services generally allow the professional interpretation component of a test to be billed separately from the technical component. Its NeoFISH, NeoFLOW and other tech-only service offerings allow properly trained and credentialed community-based pathologists to extend their own practices by performing ! professional interpretations services.
The Company's tech-only services are designed to give pathologists the option to choose, on a case by case basis, whether they want to order just the technical information and images relating to a specific test so they can perform the professional interpretation, or order global services and receive a test report, which includes a NeoGenomics Pathologist�� interpretation of the test results.
The Company also offers a set of global services to meet the needs of those clients who are not credentialed and trained in interpreting genetic tests and who are looking for specialists to interpret the testing results for them. In its global service offerings, its lab performs the technical component of the tests and its doctor of medicine (M.D.s) and doctor of philosophy (Ph.D) s to provide the interpretation services. Its genetic pathology solutions (GPS) report summarizes all relevant case data from its global services on one summary report.
The Company competes with General Electric Healthcare Services and Novartis, A.G.
Advisors' Opinion:- [By John Udovich]
One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�
Top 5 Gas Utility Stocks For 2014: OceanFirst Financial Corp.(OCFC)
OceanFirst Financial Corp. operates as the holding company for OceanFirst Bank that provides community banking services to retail, government, and business customers primarily in Ocean, Monmouth, and Middlesex counties in New Jersey. Its deposit products include money market accounts, savings accounts, interest-bearing checking accounts, non-interest bearing accounts, and time deposits. The company?s loan portfolio comprises conventional first mortgage loans secured by one-to-four family residences, residential mortgage loans, commercial real estate loans, multi-family and land loans, and real estate construction loans; consumer loans, such as home equity loans and lines of credit; and commercial loans. In addition, it offers trust and asset management, and merchant check card services; and sells alternative investment products, including mutual funds, annuities, and life insurance. The company operates 22 branches, as well as a loan production office and a trust and weal th management office. OceanFirst Financial Corp. was founded in 1902 and is based in Toms River, New Jersey.
Advisors' Opinion:- [By Garrett Cook]
In trading on Wednesday, financial shares were relative laggards, down on the day by about 0.24 percent. Top losers in the sector included IRSA Investments and Representations (NYSE: IRS), down 3.2 percent, and OceanFirst Financial (NASDAQ: OCFC), off 2.5 percent.
No comments:
Post a Comment